The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Open accessAbstract
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary between health and disease. In spite of its central role in physiological homeostasis, it provides the oxygen and nutrition needed by tumor cells to proceed from dormancy if pro-angiogenic factors tip the balance in favor of tumor angiogenesis. Among pro-angiogenic factors, vascular endothelial growth factor (VEGF) is a prominent target in therapeutic methods due to its strategic involvement in the formation of anomalous tumor vasculature. In addition, VEGF exhibits immune-regulatory properties which suppress immune cell antitumor activity. VEGF signaling through its receptors is an integral part of tumoral angiogenic approaches. A wide variety of medicines have been designed to target the ligands and receptors of this pro-angiogenic superfamily. Herein, we summarize the direct and indirect molecular mechanisms of VEGF to demonstrate its versatile role in the context of cancer angiogenesis and current transformative VEGF-targeted strategies interfering with tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Signaling Vascular Morphogenesis and Maintenance
Hanahan, D. (1997) · Science · doi:10.1126/science.277.5322.48 · Cited by 1,190
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici, C. S., Boşca, A. B., Șușman, S., Mărginean, M. V., Mihu, C., Istrate, M., Moldovan, I. M., Roman, A. L., & Mihu, C. M. (2018) · PubMed · Cited by 1,146
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., Tewari, K. S., Salman, P., Hoyos Usta, E., Yañez, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112435 · Cited by 1,067
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Quintero-Fabián, S., Arreola, R., Becerril-Villanueva, E., Torres-Romero, J. C., Arana-Argáez, V., Lara-Riegos, J., Ramírez-Camacho, M. A., & Alvarez-Sánchez, M. E. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01370 · Cited by 1,036
Gavard, J., & Gutkind, J. S. (2006) · Nature Cell Biology · doi:10.1038/ncb1486 · Cited by 1,018
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Makker, V., Colombo, N., Casado Herráez, A., Santin, A. D., Colomba, E., Miller, D. S., Fujiwara, K., Pignata, S., Baron-Hay, S., Ray-Coquard, I., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2108330 · Cited by 930
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 899
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Claesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
Li, J., Qin, S., Xu, R., Yau, T. C. C., Ma, B., Pan, H., Xu, J., Bai, Y., Chi, Y., Wang, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70156-7 · Cited by 813
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Kim, I., Moon, S.-O., Hoon Kim, S., Jin Kim, H., Soon Koh, Y., & Young Koh, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009705200 · Cited by 760
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Kabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31607-0 · Cited by 684
Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer
Kong, D.-H., Kim, Y., Kim, M., Jang, J., & Lee, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041057 · Cited by 683
Fagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis
Riabov, V., Gudima, A., Wang, N., Mickley, A., Orekhov, A., & Kzhyshkowska, J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00075 · Cited by 628
Han, B., Li, K., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Zhao, Y., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3039 · Cited by 614
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Takahashi, T., Ueno, H., & Shibuya, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202527 · Cited by 571
Basic and Therapeutic Aspects of Angiogenesis Updated
Eelen, G., Treps, L., Li, X., & Carmeliet, P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316851 · Cited by 568
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Méndez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 505
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
Thijssen, V. L. J. L., Postel, R., Brandwijk, R. J. M. G. E., Dings, R. P. M., Nesmelova, I., Satijn, S., Verhofstad, N., Nakabeppu, Y., Baum, L. G., Bakkers, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603883103 · Cited by 497
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
Guo, F., Wang, Y., Liu, J., Mok, S. C., Xue, F., & Zhang, W. (2016) · Oncogene · doi:10.1038/onc.2015.139 · Cited by 468
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
Li, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.7855 · Cited by 425
Deryugina, E. I., & Quigley, J. P. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.04.004 · Cited by 422
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
The roles of tumor-associated macrophages in tumor angiogenesis and metastasis
Fu, L.-Q., Du, W.-L., Cai, M.-H., Yao, J.-Y., Zhao, Y.-Y., & Mou, X.-Z. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104119 · Cited by 415
Shigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., Kikuchi, H., Mamessier, E., Aoki, S., Ramjiawan, R. R., et al. (2020) · Hepatology · doi:10.1002/hep.30889 · Cited by 409
The role of the Angiopoietins in vascular morphogenesis
Thomas, M., & Augustin, H. G. (2009) · Angiogenesis · doi:10.1007/s10456-009-9147-3 · Cited by 405
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.012 · Cited by 398
Cohen, M. H., Gootenberg, J., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-713 · Cited by 396
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Chemokines in health and disease
Raman, D., Sobolik-Delmaire, T., & Richmond, A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.01.005 · Cited by 366
Kim, C., & Prasad, V. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5868 · Cited by 354
Focus on lymphangiogenesis in tumor metastasis
Achen, M. G., McColl, B. K., & Stacker, S. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.017 · Cited by 351
Duan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Liao, D., Corle, C., Seagroves, T. N., & Johnson, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2701 · Cited by 339
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response
Markowska, A. I., Liu, F.-T., & Panjwani, N. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090121 · Cited by 330
“Sprouting angiogenesis”, a reappraisal
Ribatti, D., & Crivellato, E. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.09.018 · Cited by 325
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
Belotti, D., Paganoni, P., Manenti, L., Garofalo, A., Marchini, S., Taraboletti, G., & Giavazzi, R. (2003) · PubMed · Cited by 318
Raica, M., & Cimpean, A. M. (2010) · Pharmaceuticals · doi:10.3390/ph3030572 · Cited by 304
Targeting MCL-1 in cancer: current status and perspectives
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 301
Tannock, I. F., Fizazi, K., Ivanov, S., Karlsson, C. T., Fléchon, A., Skoneczna, I., Orlandi, F., Gravis, G., Matveev, V., Bavbek, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70184-0 · Cited by 288
A novel mechanism of capillary growth in the rat pulmonary microcirculation
Burri, P. H., & Tarek, M. R. (1990) · The Anatomical Record · doi:10.1002/ar.1092280107 · Cited by 288
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M., & Konishi, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0387 · Cited by 275
Korbecki, J., Kojder, K., Kapczuk, P., Kupnicka, P., Gawrońska-Szklarz, B., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020843 · Cited by 273
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00602-3 · Cited by 267
Holmqvist, K., Cross, M. J., Rolny, C., Hägerkvist, R., Rahimi, N., Matsumoto, T., Claesson-Welsh, L., & Welsh, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312729200 · Cited by 265
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
VEGF may contribute to macrophage recruitment and M2 polarization in the decidua
Wheeler, K. C., Jena, M. K., Pradhan, B. S., Nayak, N., Das, S., Hsu, C.-D., Wheeler, D. S., Chen, K., & Nayak, N. R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191040 · Cited by 258
Brose, M. S., Robinson, B., Sherman, S. I., Krajewska, J., Lin, C.-C., Vaisman, F., Hoff, A. O., Hitre, E., Bowles, D. W., Hernando, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00332-6 · Cited by 256
Zhang, P.-F., Li, K.-S., Shen, Y.-H., Gao, P.-T., Dong, Z.-R., Cai, J.-B., Zhang, C., Huang, X.-Y., Tian, M.-X., Hu, Z.-Q., et al. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.324 · Cited by 247
Reactive oxygen species and cancer: A complex interaction
Saikolappan, S., Kumar, B., Shishodia, G., Koul, S., & Koul, H. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.020 · Cited by 247
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041388 · Cited by 246
Ledermann, J. A., Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01167-8 · Cited by 237
Hypoxia-Inducible Factor as an Angiogenic Master Switch
Hashimoto, T., & Shibasaki, F. (2015) · Frontiers in Pediatrics · doi:10.3389/fped.2015.00033 · Cited by 231
Masoumi Moghaddam, S., Amini, A., Morris, D. L., & Pourgholami, M. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9337-5 · Cited by 228
Self-citationMarkowska, A. I., Jefferies, K. C., & Panjwani, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.226423 · Cited by 218
Bruno, A., Mortara, L., Baci, D., Noonan, D. M., & Albini, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00771 · Cited by 215
Rudge, J. S., Holash, J., Hylton, D., Russell, M., Jiang, S., Leidich, R., Papadopoulos, N., Pyles, E. A., Torri, A., Wiegand, S. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708865104 · Cited by 203
Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, X., Li, Z., Li, E., Yuan, X., Chi, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30493-9 · Cited by 197
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
Li, Y.-L., Li, Y.-L., Zhao, H., Ren, X.-B., Zhao, H., & Ren, X.-B. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2015.0070 · Cited by 196
Xu, J., Shen, L., Zhou, Z., Li, J., Bai, C., Chi, Y., Li, Z., Xu, N., Li, E., Liu, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30496-4 · Cited by 196
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Sun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13009 · Cited by 189
Ramlau, R., Gorbunova, V., Ciuleanu, T. E., Novello, S., Ozguroglu, M., Goksel, T., Baldotto, C., Bennouna, J., Shepherd, F. A., Le-Guennec, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6932 · Cited by 188
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy-Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 184
Mechanical Forces in Tumor Angiogenesis
Zanotelli, M. R., & Reinhart‐King, C. A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95294-9_6 · Cited by 180
Arora, S., Balasubramaniam, S., Zhang, H., Berman, T., Narayan, P., Suzman, D., Bloomquist, E., Tang, S., Gong, Y., Sridhara, R., et al. (2021) · The Oncologist · doi:10.1002/onco.13551 · Cited by 180
Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion
Perrot-Applanat, M., & Di Benedetto, M. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.23332 · Cited by 170
Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis
Hisada, Y., & Mackman, N. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687894 · Cited by 169
Ziogas, A. C., Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Terpos, E., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26094 · Cited by 168
MCL-1 inhibition in cancer treatment
Xiang, W., Yang, C., & Bai, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s146228 · Cited by 167
Heterogeneity of Tumor Endothelial Cells
Ohga, N., Ishikawa, S., Maishi, N., Akiyama, K., Hida, Y., Kawamoto, T., Sadamoto, Y., Osawa, T., Yamamoto, K., Kondoh, M., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.035 · Cited by 166
Artificial intelligence in cancer therapy
Ho, D. (2020) · Science · doi:10.1126/science.aaz3023 · Cited by 164
Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context
Geindreau, M., Bruchard, M., & Végran, F. (2022) · Cancers · doi:10.3390/cancers14102446 · Cited by 156
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang, Y., & Brekken, R. A. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0222-082r · Cited by 155
Alternatively spliced tissue factor induces angiogenesis through integrin ligation
van den Berg, Y. W., van den Hengel, L. G., Myers, H. R., Ayachi, O., Jordanova, E. S., Ruf, W., Spek, C. A., Reitsma, P. H., Bogdanov, V. Y., & Versteeg, H. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905325106 · Cited by 150
VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread
Li, X., Padhan, N., Sjöström, E. O., Roche, F. P., Testini, C., Honkura, N., Sáinz-Jaspeado, M., Gordon, E., Bentley, K., Philippides, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11017 · Cited by 149
Blumenthal, G. M., Cortazar, P., Zhang, J. J., Tang, S. W., Sridhara, R., Murgo, A. J., Justice, R. L., & Pazdur, R. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0044 · Cited by 148
Ayoub, N. M., Jaradat, S. K., Al-Shami, K. M., & Alkhalifa, A. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838133 · Cited by 148
Courau, T., Nehar-Belaid, D., Flórez, L. V., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., & Klatzmann, D. (2016) · JCI Insight · doi:10.1172/jci.insight.85974 · Cited by 143
The Ikaros family in lymphocyte development
Heizmann, B., Kastner, P., & Chan, S. H. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.11.005 · Cited by 141
Hlushchuk, R., Riesterer, O., Baum, O., Wood, J. M., Gruber, G., Pruschy, M. N., & Djonov, V. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071131 · Cited by 139
Mimura, K., Kono, K., Takahashi, A., Kawaguchi, Y., & Fujii, H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0234-7 · Cited by 138
Tissue factor in cancer progression and angiogenesis
Ruf, W., Yokota, N., & Schaffner, F. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70010-4 · Cited by 138
Isolated tumor endothelial cells maintain specific character during long-term culture
Matsuda, K., Ohga, N., Hida, Y., Muraki, C., Tsuchiya, K., Kurosu, T., Akino, T., Shih, S., Totsuka, Y., Klagsbrun, M., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.089 · Cited by 137
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
Suzuki, H. Y., Onishi, H., 和田, 純., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., & Katano, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200939887 · Cited by 136
Mackey, J. R., Ramos-Vázquez, M., Lipatov, O. N., McCarthy, N. J., Krasnozhon, D., Семиглазов, В. Ф., Manikhas, A., Gelmon, K. A., Konecny, G. E., Webster, M. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1513 · Cited by 136
Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response
Geindreau, M., Ghiringhelli, F., & Bruchard, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094871 · Cited by 135
Tumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 134
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Zhang, Q., Lou, Y., Zhang, J., Fu, Q., Wei, T., Sun, X., Chen, Q., Yang, J., Bai, X., & Liang, T. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0689-5 · Cited by 129
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
Beyond thrombosis: the impact of tissue factor signaling in cancer
Unruh, D. J., & Horbinski, C. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00932-z · Cited by 117
Pourgholami, M. H., Akhter, J., Wang, L. E., Lu, Y., & Morris, D. L. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0927-6 · Cited by 112
Self-citationHuang, X. L., Khan, M. I., Wang, J., Ali, R., Ali, S. W., Zahra, Q. U. A., Kazmi, A., Lolai, A., Huang, Y., Hussain, A., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.075 · Cited by 109
Neutrophil-Derived Cytokines Involved in Physiological and Pathological Angiogenesis
Tecchio, C., & Cassatella, M. A. (2013) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000353358 · Cited by 107
Endothelial cell plasticity at the single-cell level
Pasut, A., Becker, L. M., Cuypers, A., & Carmeliet, P. (2021) · Angiogenesis · doi:10.1007/s10456-021-09797-3 · Cited by 107
Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis
Chung, M. S., & Han, S. J. (2022) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2022.856316 · Cited by 107
The functional role of cell adhesion molecules in tumor angiogenesis
Francavilla, C., Maddaluno, L., & Cavallaro, U. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.004 · Cited by 106
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
Summers, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0250 · Cited by 106
The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Amini, A., Moghaddam, S. M., Morris, D. L., & Pourgholami, M. H. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912798888956 · Cited by 105
Self-citationAzevedo-Martins, J. M., Rabelo‐Santos, S. H., Westin, M. C. D. A., & Zeferino, L. C. (2020) · BMC Cancer · doi:10.1186/s12885-020-07150-3 · Cited by 105
Hosaka, K., Yang, Y., Seki, T., Du, Q., Xu, J., He, X., Wu, J., Zhang, Y., Morikawa, H., Nakamura, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17525-6 · Cited by 105
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
Haunschild, C., & Tewari, K. S. (2019) · Future Oncology · doi:10.2217/fon-2019-0042 · Cited by 103
Hossein Pourgholami, M., Yan Cai, Z., Lu, Y., Wang, L., & Lawson Morris, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1181 · Cited by 100
Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
Strickler, J. H., & Hurwitz, H. I. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0003 · Cited by 95
Wu, X., Giobbie‐Hurder, A., Liao, X., Lawrence, D. P., McDermott, D. F., Zhou, J. M., Rodig, S. J., & Hodi, F. S. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0084 · Cited by 94
Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis
Rondon, A. M. R., Kroone, C., Kapteijn, M. Y., Versteeg, H. H., & Buijs, J. T. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687895 · Cited by 94
Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry
Zhang, X. Z., Zhang, J., Zhou, H., Fan, G., & Li, Q. (2019) · Journal of Cancer · doi:10.7150/jca.34171 · Cited by 93
Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation
dos Santos, S. N., Sheldon, H., Pereira, J. X., Paluch, C., Bridges, E., El-Cheikh, M. C., Harris, A. L., & Bernardes, E. S. (2017) · Oncotarget · doi:10.18632/oncotarget.17718 · Cited by 91
Xu, Y., Yang, Q., Liu, T., Li, K., Liu, Y., Zhu, C., Zhang, Z., Li, L., Zhang, C., Xie, M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.054 · Cited by 87
Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies
López-Pedrera, C., Barbarroja, N., Dorado, G., Siendones, E., & Velasco, F. (2006) · Leukemia · doi:10.1038/sj.leu.2404264 · Cited by 85
Barr, M. P., Gray, S. G., Gately, K. A., Hams, E., Fallon, P. G., Davies, A. M., Richard, D. J., Pidgeon, G. P., & O'Byrne, K. J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0310-8 · Cited by 81
Hirte, H. W., Lheureux, S., Fleming, G. F., Sugimoto, A. K., Morgan, R. J., Biagi, J. J., Wang, L., McGill, S., Ivy, S. P., & Oza, A. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.009 · Cited by 80
Magnusson, P. U., Looman, C., Åhgren, A., Wu, Y. L., Claesson, L., & Heuchel, R. L. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000282198.60701.94 · Cited by 79
Cited by
Research progress on interferon and cellular senescence
Wang, D., Chen, K., Wang, Z., Wu, H., & Li, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202400808rr · Cited by 23
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Tracing unknown tumor origins with a biological-pathway-based transformer model
Xie, J., Chen, Y., Luo, S., Yang, W., Lin, Y., Wang, L., Ding, X., Tong, M., & Yu, R. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100797 · Cited by 9
Metadata
- Authors
- Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 949
- Pages
- 175586
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W4323660090
- Cited by
- 362
- References
- 256
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.